SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Strategy, Inc. engages in the development of fixed-income instruments that provide investors varying degrees of economic exposure to bitcoin. It executes bitcoin acquisition, capital management, and capital markets strategies. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - Ordinary Shares - Class A

Strategy

Bitcoins selloff amid concerns over a reported Binance security breach is weighing on Strategy shares, with traders debating whether the crypto-market shock signals deeper trouble or a buying opportunity. Concerns about Strategys quarterly results and CFO transition add to the bearish discussion, while some investors expect a rebound.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

DaVitas warning that DefenCaths Medicare add-on reimbursement could decline sharply after the first quarter of 2027 has fueled concern about pricing and CorMedixs largest revenue driver, alongside a steep selloff. Traders disagree on whether the comments signal a lasting revenue threat or are preliminary, DaVita-specific estimates with limited visibility into future reimbursement and utilization.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TGTX has reached fresh 52-week highs, with traders focused on an expected Q3 earnings report and debating whether the rally reflects BRIUMVI growth expectations or speculative buyout hopes and short covering. The buyout talk remains unconfirmed, and the earnings date has not been officially confirmed.

Whirlpool Corp. engages in the manufacturing and marketing of home appliances. Its products include home laundry appliances, refrigerators and freezers, cooking appliances, home dishwashers, and room air-conditioning equipment, mixers, and portable household appliances. The firm's brands include Whirlpool, KitchenAid, Maytag, Consul, Brastemp, Amana, Bauknecht, JennAir, and Indesit. It operates through the following geographical segments: Major Domestic Appliances (MDA) North America, Major Domestic Appliances (MDA) Latin America, Small Domestic Appliances (SDA) Global, and Others. The company was founded by Emory Upton, Fred Upton, and Louis C. Upton on November 11, 1911 and is headquartered in Benton Harbor, MI.

Whirlpool Corp.

Whirlpools weak Q1 results, sharply reduced full-year outlook and dividend suspension have driven attention, as the company cited recession-level appliance demand and blamed the Iran war and collapsing consumer confidence. Many traders are alarmed by the worsening outlook and debt burden, while some see the selloff as an overreaction and are buying for a possible rebound.

CVS Health Corp. is a health solutions company, which engages in the provision of healthcare services. It operates through the following segments: Health Care Benefits, Health Services, Pharmacy and Consumer Wellness, and Corporate and Other. The Health Care Benefits segment operates as a health care benefits provider. The Health Services segment offers a full range of PBM solutions, delivers health care services in its medical clinics, virtually, and in the home. The Pharmacy & Consumer Wellness segment dispenses prescriptions in its retail pharmacies and through its infusion operations. The Corporate and Other Segment is involved in management and administrative expenses. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and is headquartered in Woonsocket, RI.

CVS Health Corp

Weaker 2027 Medicare Advantage star ratings for Aetna are driving concern about lost bonus payments and future margin pressure. Traders are comparing CVSs weakness with Humanas rally on improved ratings, while debating whether the setback is already priced in.

Corvus Pharmaceuticals, Inc. engages in the development of product candidates for the treatment of cancer and immune-mediated and inflammatory diseases. Its product candidates include soquelitinib, an ITK inhibitor, ciforadenant, an adenosine A2A receptor antagonist, and mupadolimab, a B cell-activating anti-CD73 antibody. The company was founded by Richard A. Miller, Peter A. Thompson, Joseph J. Buggy, and Erik Verner on January 27, 2014 and is headquartered in South San Francisco, CA.

Corvus Pharmaceuticals Inc

Traders are focused on a possible update on Corvuss ALPS program around the ASH abstract release and a company call, though the timing and whether the data will be disclosed remain uncertain. Optimism about a potential catalyst is countered by concerns over past delays, managements limited updates and heavy short interest.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

RASONQUE (daraxonrasib), Revolution Medicines pancreatic cancer therapy, remains the main focus: traders cite its Phase 3 survival results and FDA approval as support for the companys commercial and broader RAS-drug pipeline prospects. Discussion is also divided over valuation and efficacy across KRAS subtypes, with some traders pointing to competition from selective G12D drugs such as Verastems VS-7375.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances updated NSCLC trial results and shift toward biomarker-selected lung-cancer studies are driving attention: the overall response rate was 24.6%, while a retrospective subgroup showed a stronger signal, but the lung-cancer filing is expected in 2027 and durability remains uncertain. Traders are divided between viewing the selloff as an overreaction to promising precision-treatment data and seeing a narrower, delayed opportunity compounded by managements confusing presentation.

Apple, Inc. engages in the design, manufacture, and sale of smartphones, personal computers, tablets, wearables and accessories, and other varieties of related services. It operates through the following geographical segments: Americas, Europe, Greater China, Japan, and Rest of Asia Pacific. The Americas segment includes North and South America. The Europe segment consists of European countries, as well as India, the Middle East, and Africa. The Greater China segment comprises China, Hong Kong, and Taiwan. The Rest of Asia Pacific segment includes Australia and Asian countries. Its products and services include iPhone, Mac, iPad, AirPods, Apple TV, Apple Watch, Beats products, AppleCare, iCloud, digital content stores, streaming, and licensing services. The company was founded by Steven Paul Jobs, Ronald Gerald Wayne, and Stephen G. Wozniak in April 1976 and is headquartered in Cupertino, CA.

Apple Inc

Apples fiscal fourth-quarter earnings report is the focus, with traders debating whether its premium valuation can be justified amid memory-cost pressures and concerns about iPhone demand and upgrade cycles. Some expect a sharp post-report drop, while others view Apples restrained AI spending and relative resilience during the tech selloff as supporting its safe-haven appeal.

Arrowhead Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development of medicines that treat intractable diseases by silencing the genes that cause them. The firms preclinical stage drug candidates include ARO-ANG3, ARO-AAT, ARO-APOC3, ARO-HIF2, ARO-HSD, ARO-Lung2, ARO-COV, and ARO-ENaC. The company was founded by Robert Bruce Stewart in 1989 and is headquartered in Pasadena, CA.

Arrowhead Pharmaceuticals Inc.

Arrowheads interim ARO-MAPT resultsshowing substantial tau reduction and supporting subcutaneous delivery of RNAi to the central nervous systemare a major focus. Traders broadly view the data as encouraging platform validation, but many are frustrated that the share price has not reflected the positive results and debate whether the weakness is market-driven or a sell-the-news reaction.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Should You Invest in the State Street SPDR S&P Bank ETF (KBE)?

Is State Street SPDR S&P Bank ETF (KBE) a Strong ETF Right Now?

Bank ETFs in Spotlight as Next Week's Fed Rate Hike Odds Hit 70%

Bank ETFs are in focus as rising inflation lifts Fed rate hike odds, creating potential tailwinds and risks for the banking sector.

Bank ETFs: An Overlooked Winner of AI Boom

AI infrastructure spending is fueling broader commercial loan demand, creating a potential growth opportunity for bank ETFs beyond data center financing.

 Play Earnings Growth Momentum With These ETFs

Robust Q2 earnings momentum is likely to fuel a broader market rally. These ETFs are well positioned to benefit from the scenario.

Sector ETFs to Win on Q2 Earnings Growth Potential 

Q2 earnings are off to a strong start. Tech, Energy, Materials, Finance and Aerospace ETFs could shine as profit growth broadens across sectors.

Big Banks to Hit Earnings Season With High Hopes: ETFs in Focus

Big bank earnings are here. Positive Earnings ESPs, and healthy fundamentals put financial ETFs like IYG, KBE and VFH in focus. Can the rally last?

Top Wall Street Banks Kick Off Q2 Earnings Next Week — Here's What Analysts Expect

Equity

Bank of America, JPMorgan Chase, Citigroup, Wells Fargo and Goldman Sachs are scheduled to report quarterly earnings on July 14. 

SPDR Series Trust - State Street SPDR S&P Bank ETF

Neutral Sentiment

<ul class="summary-bullets"><li>The State Street SPDR S&amp;P Bank ETF is trading near a record high, up 12% in 2026.</li><li>U.S. consumer spending in June showed its strongest growth since April 2022.</li><li>“Second-quarter earnings are already priced in, potentially leading to a sell-the-news response,” Evercore analyst Glenn Schorr told Barron’s.</li></ul>America’s largest banks are scheduled to report quarterly earnings beginning Tuesday next week, on the back of strong consumer spending as inflation remains sticky.&nbsp;U.S. consumer spending in June showed its strongest growth since April 2022, with Bank of America reporting a 6.3% year-over-year increase in aggregate credit and debit card spending per household in June.Supporting strong spending metrics, the State Street SPDR S&amp;P Bank ETF (KBE) is trading near a record high and has gained about 12% in 2026. However, gains are skewed towards some players. Wells Fargo is down 8% year-to-date, while Citi has jumped 17%. Bank of America and JPMorgan are up 6% and 3% this year, respectively.&nbsp;Despite record-high equity markets, a resurgence in mergers and acquisitions, and a strong slate of initial public offerings, the current capital markets cycle may still have further upside, Evercore ISI analyst Glenn Schorr told Barron’s.&nbsp;“Second-quarter earnings are already priced in, potentially leading to a "sell-the-news" response, Schorr added.&nbsp;Most of the above mentioned banks also happen to be lead bookrunners for upcoming IPOs by OpenAI and Anthropic.&nbsp;<h2 class="st-heading-2">BAC, JPM, C, WFC, GS Q2 Earnings And Revenue Outlook</h2>Bank of America has beat revenue expectations for the past three consecutive quarters and has surged past earnings expectations for the past eight quarters, as per&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://fiscal.ai">Fiscal.ai</a>. Analysts expect earnings of $1.13 per share, nearly 27% higher YoY and revenue of $30.8 billion for the quarter ending June 2026, up 16%.JPMorgan Chase has an earnings outlook of $5.7 per share and revenue expectations of $51.2 billion. The bank has beaten on earnings in each of its last eight quarters, and shares sit near $338 against an average analyst target of $350.Meanwhile, Citigroup’s Q2 revenue is expected to come in at $23.73 billion with earnings of $2.71 per share.&nbsp;Across the investment banks and managers group, Q2 earnings are expected to grow 10.4% on 10.7% higher revenues. Most of that comes from core banking and trading, with investment banking broadly stable rather than booming, according to IG data.&nbsp;Despite growing earnings, most banks continue to trade at cheap valuations, sitting at around 12 times earnings compared to 22 times for the S&amp;P 500, according to IG Markets. Market consensus indicates an 11% earnings growth for the banking sector in 2026, suggesting that this discount is not overly extended, even though a low multiple on its own guarantees nothing.<h2 class="st-heading-2">BAC, JPM, C Stock: Retail View&nbsp;</h2>Retail sentiment on Stocktwits for BAC, JPM and C stock were all in the ‘neutral’ zone with ‘normal’ message volumes.&nbsp;<a href="https://stocktwits.com/symbol/BAC">BAC Stock</a> has jumped 6.4%, <a href="https://stocktwits.com/symbol/C">C stock</a> gained 17%, and <a href="https://stocktwits.com/symbol/JPM">JPM</a> rose 3% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/aapl-stock-unmoved-after-hours-apple-sues-open-ai-over-alleged-rotten-campaign-to-steal-ai-hardware-secrets/cZmrj2wR78n">AAPL Stock Unmoved After-Hours — Apple Sues OpenAI Over Alleged 'Rotten' Campaign To Steal AI Hardware Secrets</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Multiple one hundred dollar bills featuring benjamin franklin are scattered and overlapping, creating a background of american currency, ideal for financial concepts

America’s largest banks are scheduled to report quarterly earnings beginning Tuesday next week, on the back of strong consumer spending as inflation remains sticky.&nbsp;

Bank of America Corp

Citigroup Inc

Goldman Sachs Group, Inc.

JPMorgan Chase & Co

SPDR S&P Bank ETF

Invesco KBW Bank ETF

Wells Fargo & Co.

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Feed

News

Sentiment

Fundamentals

Info

KBE SPDR S&P Bank ETF

Fundamentals

Latest KBE News